NCT05938088 is a NA clinical trial of Arm I (mirogabalin group) in Hip Osteoarthritis, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT05938088?

NCT05938088 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT05938088?

Interventions in NCT05938088: Arm I (mirogabalin group), Arm II (placebo group).

What condition does NCT05938088 study?

NCT05938088 studies Hip Osteoarthritis.

Is NCT05938088 still recruiting?

NCT05938088 is currently status unknown. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05938088

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mirogabalin for Total Hip Arthroplasty

Status unknown NA Last updated 14 August 2023

What this trial tests

NA trial testing Arm I (mirogabalin group) in Hip Osteoarthritis in 56 participants. Status unknown.

Timeline

20 July 2023

Primary endpoint
28 June 2025

28 June 2025

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	quadruple
Primary purpose	treatment
Enrollment	56
Start date	20 July 2023
Primary completion	28 June 2025
Estimated completion	28 June 2025
Sites	1 location across South Korea

Drugs / interventions tested

Arm I (mirogabalin group) — full drug profile →
Arm II (placebo group)

Conditions studied

Hip Osteoarthritis — all drugs for Hip Osteoarthritis →

Sponsor

Gangnam Severance Hospital

Who can join

19 and older, any sex, with Hip Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to confirm the analgesic effect of mirogabalin in patients undergoing unilateral hip arthroplasty.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hip Osteoarthritis

Currently open trials in the same condition.

NCT07330999 — Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults · NA · recruiting
NCT07327931 — PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults · NA · recruiting
NCT07288983 — PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery · NA · recruiting
NCT07327372 — PENG Block With Dexmedetomidine in Older Adults · NA · recruiting
NCT07347041 — Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA) · NA · recruiting

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05938088 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05938088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing